Clearpoint Neuro Inc
CLPT15.810USD
-2.420-13.27%
Close 11/07, 16:00（ET）Quotes delayed by 15 min
449.45MMarket Cap
LossP/E TTM
More Details of Clearpoint Neuro Inc Company
ClearPoint Neuro, Inc. is a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company provides both clinical products as well as pre-clinical development services for controlled drug and device delivery. The Company’s flagship product is the ClearPoint Neuro Navigation System. Its initial product offering, the ClearPoint system, is an integrated system comprised of capital equipment and disposable products, designed to allow minimally invasive procedures in the brain to be performed in a magnetic resonance imaging (MRI) suite. The ClearPoint Array Neuro Navigation System and its principal disposable component is designed to be deployed in an operating room setting while also being usable in an MRI suite. It is engaged with healthcare and research centers in North America, Europe, Asia, and South America. It also provides solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide.
Clearpoint Neuro Inc Info
Ticker SymbolCLPT
Company nameClearpoint Neuro Inc
IPO dateJul 03, 2019
CEOMr. Joseph Michael Burnett
Number of employees115
Security typeOrdinary Share
Fiscal year-endJul 03
Address120 S. Sierra Avenue
CitySOLANA BEACH
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code92075
Phone19499006833
Websitehttps://www.clearpointneuro.com/
Ticker SymbolCLPT
IPO dateJul 03, 2019
CEOMr. Joseph Michael Burnett
Company Executives of Clearpoint Neuro Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Joseph Michael Burnett
Mr. Joseph Michael Burnett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
276.08K
-4.84%
Mr. Timothy T. Richards
Mr. Timothy T. Richards
Independent Director
Independent Director
78.87K
+0.71%
Dr. Matthew B. Klein, M.D.
Dr. Matthew B. Klein, M.D.
Independent Director
Independent Director
50.52K
+71.68%
Mr. Mazin Sabra
Mr. Mazin Sabra
Chief Operating Officer
Chief Operating Officer
44.08K
-14.51%
Ms. Lynnette C. Fallon
Ms. Lynnette C. Fallon
Independent Director
Independent Director
40.90K
-19.96%
Mr. Danilo D' Alessandro
Mr. Danilo D' Alessandro
Chief Financial Officer
Chief Financial Officer
--
--
Ms. B. Kristine (Kris) Johnson
Ms. B. Kristine (Kris) Johnson
Independent Director
Independent Director
--
--
Dr. Linda M. Liau
Dr. Linda M. Liau
Independent Director
Independent Director
--
--
Mr. Jeremy L. Stigall
Mr. Jeremy L. Stigall
Chief Business Officer
Chief Business Officer
--
--
Mr. R. John Fletcher
Mr. R. John Fletcher
Independent Chairman of the Board
Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Joseph Michael Burnett
Mr. Joseph Michael Burnett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
276.08K
-4.84%
Mr. Timothy T. Richards
Mr. Timothy T. Richards
Independent Director
Independent Director
78.87K
+0.71%
Dr. Matthew B. Klein, M.D.
Dr. Matthew B. Klein, M.D.
Independent Director
Independent Director
50.52K
+71.68%
Mr. Mazin Sabra
Mr. Mazin Sabra
Chief Operating Officer
Chief Operating Officer
44.08K
-14.51%
Ms. Lynnette C. Fallon
Ms. Lynnette C. Fallon
Independent Director
Independent Director
40.90K
-19.96%
Mr. Danilo D' Alessandro
Mr. Danilo D' Alessandro
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Products: Functional neurosurgery
3.43M
37.24%
Services: Biologics and drug delivery
2.87M
31.12%
Products: Biologics and drug delivery
1.87M
20.30%
Product Systems and software products
694.00K
7.53%
Services: Capital equipment and other
350.00K
3.80%
By RegionUSD
Name
Revenue
Proportion
United States
9.21M
100.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Products: Functional neurosurgery
3.43M
37.24%
Services: Biologics and drug delivery
2.87M
31.12%
Products: Biologics and drug delivery
1.87M
20.30%
Product Systems and software products
694.00K
7.53%
Services: Capital equipment and other
350.00K
3.80%
Shareholding Stats
Updated: Wed, Oct 22
Updated: Wed, Oct 22
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
5.28%
The Vanguard Group, Inc.
5.27%
Bigger Capital Funds, LP
4.10%
PTC Therapeutics Inc
3.15%
Geode Capital Management, L.L.C.
2.20%
Other
80.01%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
5.28%
The Vanguard Group, Inc.
5.27%
Bigger Capital Funds, LP
4.10%
PTC Therapeutics Inc
3.15%
Geode Capital Management, L.L.C.
2.20%
Other
80.01%
Shareholder Types
Shareholders
Proportion
Investment Advisor
19.70%
Investment Advisor/Hedge Fund
8.74%
Hedge Fund
7.68%
Individual Investor
5.21%
Corporation
3.15%
Research Firm
2.54%
Venture Capital
0.10%
Bank and Trust
0.09%
Pension Fund
0.08%
Other
52.71%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
230
11.01M
38.73%
+8.63K
2025Q2
225
12.82M
45.36%
+349.96K
2025Q1
230
12.08M
42.76%
-158.33K
2024Q4
216
11.35M
41.09%
+117.64K
2024Q3
204
10.32M
38.18%
-558.62K
2024Q2
199
10.56M
39.44%
-945.58K
2024Q1
197
10.90M
40.86%
+64.32K
2023Q4
197
9.84M
39.93%
-1.22M
2023Q3
198
9.05M
36.76%
-2.10M
2023Q2
200
8.72M
35.43%
-782.48K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
1.50M
5.27%
+1.13M
+307.45%
Jun 30, 2025
The Vanguard Group, Inc.
1.48M
5.19%
+191.14K
+14.89%
Jun 30, 2025
Bigger Capital Funds, LP
1.17M
4.1%
+31.67K
+2.79%
Jun 30, 2025
PTC Therapeutics Inc
894.58K
3.15%
--
--
Aug 23, 2024
Geode Capital Management, L.L.C.
624.80K
2.2%
+323.43K
+107.32%
Jun 30, 2025
District 2 Capital LP
430.17K
1.51%
+7.77K
+1.84%
Jun 30, 2025
Bigger (Michael)
378.69K
1.33%
--
--
Jun 30, 2025
State Street Investment Management (US)
333.38K
1.17%
+207.53K
+164.91%
Jun 30, 2025
Brown Advisory
330.90K
1.16%
-191.00
-0.06%
Jun 30, 2025
Lane Generational, LLC
258.43K
0.91%
+16.38K
+6.77%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Fidelity Digital Health ETF
1.58%
Invesco NASDAQ Future Gen 200 ETF
1.01%
iShares Neuroscience and Healthcare ETF
0.95%
iShares Micro-Cap ETF
0.11%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.09%
iShares Russell 2000 Growth ETF
0.04%
Motley Fool Next Index ETF
0.03%
Invesco Russell 2000 Dynamic Multifactor ETF
0.03%
iShares Russell 2000 ETF
0.02%
Proshares Ultra Russell 2000
0.02%
View more
Fidelity Digital Health ETF
Proportion1.58%
Invesco NASDAQ Future Gen 200 ETF
Proportion1.01%
iShares Neuroscience and Healthcare ETF
Proportion0.95%
iShares Micro-Cap ETF
Proportion0.11%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.09%
iShares Russell 2000 Growth ETF
Proportion0.04%
Motley Fool Next Index ETF
Proportion0.03%
Invesco Russell 2000 Dynamic Multifactor ETF
Proportion0.03%
iShares Russell 2000 ETF
Proportion0.02%
Proshares Ultra Russell 2000
Proportion0.02%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
